Philip L.S.M. Gordts

Philip L.S.M. Gordts, PhD

Languages spoken: English

Academic Information

Departments Primary - Pathology

Education History

Undergraduate Katholieke Universiteit Leuven, School of Medicine
 BS
Graduate Training Katholieke Universiteit Leuven, School of Medicine
 MS
Doctoral Training Katholieke Universiteit Leuven, School of Medicine
 PhD
Fellowship Katholieke Universiteit Leuven, School of Medicine, IWT
 Predoctoral Fellow
Fellowship University of Hamburg
 Visiting Predoctoral Fellow
Postdoctoral Fellowship University of California, San Diego
 Postdoctoral Fellow
Postdoctoral Fellowship Katholieke Universiteit Leuven, School of Medicine
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Gordts PL, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJ (2009). Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol, 29(9), 1258-64.
  2. Reekmans SM, Pflanzner T, Gordts PL, Isbert S, Zimmermann P, Annaert W, Weggen S, Roebroek AJ, Pietrzik CU (2010). Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis. Cell Mol Life Sci, 67(1), 135-45.
  3. Christoffersen C, Pedersen TX, Gordts PL, Roebroek AJ, Dahlbäck B, Nielsen LB (2010). Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ Res, 106(10), 1624-34.
  4. Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J (2011). Brown adipose tissue activity controls triglyceride clearance. Nat Med, 17(2), 200-5.
  5. Deng Y, Foley EM, Gonzales JC, Gordts PL, Li Y, Esko JD (2012). Shedding of syndecan-1 from human hepatocytes alters very low density lipoprotein clearance. Hepatology, 55(1), 277-86.
  6. Gordts PL, Bartelt A, Nilsson SK, Annaert W, Christoffersen C, Nielsen LB, Heeren J, Roebroek AJ (2012). Impaired LDL receptor-related protein 1 translocation correlates with improved dyslipidemia and atherosclerosis in apoE-deficient mice. PLoS One, 7(6), e38330.
  7. Christoffersen C, Benn M, Christensen PM, Gordts PLSM, Roebroek AJM, Frikke-Schmidt R, Tybjaerg-Hansen A, Dahlbäck B, Nielsen LB (2012). The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res, 53(10), 2198-2204.
  8. Lamanna WC, Lawrence R, Sarrazin S, Lameda-Diaz C, Gordts PL, Moremen KW, Esko JD (2012). A genetic model of substrate reduction therapy for mucopolysaccharidosis. J Biol Chem, 287(43), 36283-90.
  9. Gonzales JC, Gordts PL, Foley EM, Esko JD (2013). Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest, 123(6), 2742-51.
  10. Foley EM, Gordts PLSM, Stanford KI, Gonzales JC, Lawrence R, Stoddard N, Esko JD (2013). Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol, 33(9), 2065-74.
  11. Gordts PLSM, Foley EM, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, Nock R, Glass CK, Erbilgin A, Lusis AJ, Witztum JL, Esko JD (2014). Reducing macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced type I interferon signaling. Cell Metab, 20(5), 813-826.
  12. Akizu N, Cantagrel V, Zaki MS, Al-Gazali L, Wang X, Rosti RO, Dikoglu E, Gelot AB, Rosti B, Vaux KK, Scott EM, Silhavy JL, Schroth J, Copeland B, Schaffer AE, Gordts PL, Esko JD, Buschman MD, Field SJ, Napolitano G, Abdel-Salam GM, Ozgul RK, Sag'roglu MS, Azam M, Ismail S, Aglan M, Selim L, Mahmoud IG, Abdel-Hadi S, Badawy AE, Sadek AA, Mojahedi F, Kayserili H, Masri A, Bastaki L, Temtamy S, Müller U, Desguerre I, Casanova JL, Dursun A, Gunel M, Gabriel SB, de Lonlay P, Gleeson JG (2015). Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nat Genet, 47(5), 528-34.
  13. Weiss RJ, Gordts PL, Le D, Xu D, Esko JD, Tor Y (2015). Small molecule antagonists of cell-surface heparan sulfate and heparin-protein interactions. Chem Sci, 6(10), 5984-5993.
  14. Khalid O, Vera MU, Gordts PL, Ellinwood NM, Schwartz PH, Dickson PI, Esko JD, Wang RY (2016). Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I. PLoS One, 11(3), e0150850.
  15. Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD (2016). ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest, 126(8), 2855-66.
  16. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S (2017). Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431¿239 Patients. Arterioscler Thromb Vasc Biol, 37(3), 580-588.
  17. Tong W, Dwyer CA, Thacker BE, Glass CA, Brown JR, Hamill K, Moremen KW, Sarrazin S, Gordts PLSM, Dozier LE, Patrick GN, Tor Y, Esko JD (2017). Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain. Mol Ther, 25(12), 2743-2752.
  18. Clark AE, Sabalza M, Gordts PLSM, Spector DH (2018). Human Cytomegalovirus Replication Is Inhibited by the Autophagy-Inducing Compounds Trehalose and SMER28 through Distinctively Different Mechanisms. J Virol, 92(6).
  19. Schneider DA, Choi SH, Agatisa-Boyle C, Zhu L, Kim J, Pattison J, Sears DD, Gordts PLSM, Fang L, Miller YI (2018). AIBP protects against metabolic abnormalities and atherosclerosis. J Lipid Res, 59(5), 854-863.
  20. Fischer AW, Albers K, Krott LM, Hoffzimmer B, Heine M, Schmale H, Scheja L, Gordts PLSM, Heeren J (2018). The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins. Mol Metab, 16, 88-99.
  21. Tirronen A, Vuorio T, Kettunen S, Hokkanen K, Ramms B, Niskanen H, Laakso H, Kaikkonen MU, Jauhiainen M, Gordts PLSM, Ylä-Herttuala S (2018). Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants. Arterioscler Thromb Vasc Biol, 38(10), 2327-2337.
  22. Trieger GW, Verespy S 3rd, Gordts PLSM, Godula K (2019). Efficient Synthesis of Heparinoid Bioconjugates for Tailoring FGF2 Activity at the Stem Cell-Matrix Interface. Bioconjug Chem, 30(3), 833-840.
  23. Fischer AW, Albers K, Schlein C, Sass F, Krott LM, Schmale H, Gordts PLSM, Scheja L, Heeren J (2019). PID1 regulates insulin-dependent glucose uptake by controlling intracellular sorting of GLUT4-storage vesicles. Biochim Biophys Acta Mol Basis Dis, 1865(6), 1592-1603.
  24. Van Gool B, Storck SE, Reekmans SM, Lechat B, Gordts PLSM, Pradier L, Pietrzik CU, Roebroek AJM (2019). LRP1 Has a Predominant Role in Production over Clearance of Aß in a Mouse Model of Alzheimer's Disease. Mol Neurobiol, 56(10), 7234-7245.
  25. Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PLSM (2019). ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. J Lipid Res, 60(8), 1379-1395.
  26. Anower-E-Khuda F, Singh G, Deng Y, Gordts PLSM, Esko JD (2019). Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants. Glycobiology, 29(8), 582-592.
  27. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL (2020). Statin therapy increases lipoprotein(a) levels. Eur Heart J, 41(24), 2275-2284.
  28. Poli M, Anower-E-Khuda F, Asperti M, Ruzzenenti P, Gryzik M, Denardo A, Gordts PLSM, Arosio P, Esko JD (2019). Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. J Biol Chem, 294(36), 13292-13303.
  29. Kawanishi K, Dhar C, Do R, Varki N, Gordts PLSM, Varki A (2019). Human species-specific loss of CMP-N-acetylneuraminic acid hydroxylase enhances atherosclerosis via intrinsic and extrinsic mechanisms. Proc Natl Acad Sci U S A, 116(32), 16036-16045.
  30. Kegulian NC, Ramms B, Horton S, Trenchevska O, Nedelkov D, Graham MJ, Lee RG, Esko JD, Yassine HN, Gordts PLSM (2019). ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arterioscler Thromb Vasc Biol, 39(10), 2145-2156.
  31. Weiss RJ, Spahn PN, Toledo AG, Chiang AWT, Kellman BP, Li J, Benner C, Glass CK, Gordts PLSM, Lewis NE, Esko JD (2020). ZNF263 is a transcriptional regulator of heparin and heparan sulfate biosynthesis. Proc Natl Acad Sci U S A, 117(17), 9311-9317.
  32. Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP, Martino C, Gordts PLSM, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD (2020). SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell, 183(4), 1043-1057.e15.
  33. Dong J, He M, Li J, Pessentheiner A, Wang C, Zhang J, Sun Y, Wang WT, Zhang Y, Liu J, Wang SC, Huang PH, Gordts PL, Yuan ZY, Tsimikas S, Shyy JY (2020). microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight, 5(23).
  34. Weiss RJ, Spahn PN, Chiang AWT, Liu Q, Li J, Hamill KM, Rother S, Clausen TM, Hoeksema MA, Timm BM, Godula K, Glass CK, Tor Y, Gordts PLSM, Lewis NE, Esko JD (2021). Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate. Nat Chem Biol, 17(6), 684-692.
  35. Kawanishi K, Coker JK, Grunddal KV, Dhar C, Hsiao J, Zengler K, Varki N, Varki A, Gordts PLSM (2021). Dietary Neu5Ac Intervention Protects Against Atherosclerosis Associated With Human-Like Neu5Gc Loss-Brief Report. Arterioscler Thromb Vasc Biol, 41(11), 2730-2739.
  36. Porell RN, Follmar JL, Purcell SC, Timm B, Laubach LK, Kozirovskiy D, Thacker BE, Glass CA, Gordts PLSM, Godula K (2022). Biologically Derived Neoproteoglycans for Profiling Protein-Glycosaminoglycan Interactions. ACS Chem Biol, 17(6), 1534-1542.
  37. Ramms B, Patel S, Sun X, Pessentheiner AR, Ducasa GM, Mullick AE, Lee RG, Crooke RM, Tsimikas S, Witztum JL, Gordts PL (2022). Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. JCI Insight, 7(13).
  38. Tillo M, Lamanna WC, Dwyer CA, Sandoval DR, Pessentheiner AR, Al-Azzam N, Sarrazin S, Gonzales JC, Kan SH, Andreyev AY, Schultheis N, Thacker BE, Glass CA, Dickson PI, Wang RY, Selleck SB, Esko JD, Gordts PLSM (2022). Impaired mitophagy in Sanfilippo a mice causes hypertriglyceridemia and brown adipose tissue activation. J Biol Chem, 298(8), 102159.
  39. Ramms B, Pollow DP, Zhu H, Nora C, Harrington AR, Omar I, Gordts PLSM, Wortham M, Sander M (2022). Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes, 71(12), 2513-2529.
  40. Trieger GW, Pessentheiner AR, Purcell SC, Green CR, DeForest N, Willert K, Majithia AR, Metallo CM, Godula K, Gordts PLSM (2023). Glycocalyx engineering with heparan sulfate mimetics attenuates Wnt activity during adipogenesis to promote glucose uptake and metabolism. J Biol Chem, 299(5), 104611.
  41. DeForest N, Kavitha B, Hu S, Isaac R, Krohn L, Wang M, Du X, De Arruda Saldanha C, Gylys J, Merli E, Abagyan R, Najmi L, Mohan V, Alnylam Human Genetics, AMP-T2D Consortium, Flannick J, Peloso GM, Gordts PLSM, Heinz S, Deaton AM, Khera AV, Olefsky J, Radha V, Majithia AR (2023). Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins. Cell Genom, 3(7), 100339.
  42. Yang X, Weber AA, Mennillo E, Secrest P, Chang M, Wong S, Le S, Liu J, Benner CW, Karin M, Gordts PLSM, Tukey RH, Chen S (2023). Effects of Early Life Oral Arsenic Exposure on Intestinal Tract Development and Lipid Homeostasis in Neonatal Mice: Implications for NAFLD Development. Environ Health Perspect, 131(9), 97001.
  43. Nakamura Y, Kulkarni NN, Takahashi T, Alimohamadi H, Dokoshi T, Liu E, Shia M, Numata T, Luo EW, Gombart AF, Yang X, Secrest P, Gordts PL, Tsimikas S, Wong GC, Gallo RL (2024). Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis. J Clin Invest, 134(5).
  44. Tomazini BM, Tramujas L, Medrado FA Junior, Gomes SPDC, Negrelli KL, Murinize GS, Santos RHN, Vianna BMP, Piotto BF, Veiga TS, Santos BRD, Peneluppi Horak AC, Lemos OMC, Lopes MA, Olicheski BB, Campones DL, Peixoto LAA, Basilio ADAC, Gebara OCE, Lopes ATA, Saconato H, Valeis N, Miranda TA, Laranjeira LN, Santucci EV, Carlin AF, Esko JD, Gordts PLSM, Tsimikas S, Cavalcanti AB (2024). Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial. PLoS One, 19(2), e0299197.
  45. Chaix A, Lin T, Ramms B, Cutler RG, Le T, Lopez C, Miu P, Pinto AFM, Saghatelian A, Playford MP, Mehta NN, Mattson MP, Gordts P, Witztum JL, Panda S (2024). Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice. Arterioscler Thromb Vasc Biol, 44(9), 2069-2087.
  46. Painter CD, Sankaranarayanan NV, Nagarajan B, Mandel Clausen T, West AMV, Setiawan NJ, Park J, Porell RN, Bartels PL, Sandoval DR, Vasquez GJ, Chute JP, Godula K, Vander Kooi CW, Gordts PLSM, Corbett KD, Termini CM, Desai UR, Esko JD (2024). Alteration of Neuropilin-1 and Heparan Sulfate Interaction Impairs Murine B16 Tumor Growth. ACS Chem Biol, 19(8), 1820-1835.
  47. Pessentheiner AR, Spann NJ, Autran CA, Oh TG, Grunddal KV, Coker JK, Painter CD, Ramms B, Chiang AW, Wang CY, Hsiao J, Wang Y, Quach A, Booshehri LM, Hammond A, Tognaccini C, Latasiewicz J, Willemsen L, Zengler K, de Winther MP, Hoffman HM, Philpott M, Cribbs AP, Oppermann U, Lewis NE, Witztum JL, Yu R, Atkins AR, Downes M, Evans RM, Glass CK, Bode L, Gordts PL (2024). The human milk oligosaccharide 3'sialyllactose reduces low-grade inflammation and atherosclerosis development in mice. JCI Insight, 9(21), :e181329.
  48. Ramadoss S, Qin J, Tao B, Thomas NE, Cao E, Wu R, Sandoval DR, Piermatteo A, Grunddal KV, Ma F, Li S, Sun B, Zhou Y, Wan J, Pellegrini M, Holst B, Lusis AJ, Gordts PLSM, Deb A (2024). Bone-marrow macrophage-derived GPNMB protein binds to orphan receptor GPR39 and plays a critical role in cardiac repair. Nat Cardiovasc Res, 3(11), 1356-1373.
  49. Gioia MD, Poli V, Tan PJ, Spreafico R, Chu A, Cuenca AG, Gordts PL, Pandolfi L, Meloni F, Witztum JL, Chou J, Springstead JR, Zanoni (2023). Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter. bioRxiv,
  50. Gengatharan JM, Handzlik MK, Chih ZY, Ruchhoeft ML, Secrest P, Ashley EL, Green CR, Wallace M, Gordts PLSM, Metallo C (2024). Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans-fat-induced atherosclerosis. Cell metabolism,
  51. Sandoval DR, Clausen TM, Nora C, Cribbs AP, Denardo A, Clark AE, Garretson AF, Coker JKC, Narayanan A, Majowicz SA, Philpott M, Johansson C, Dunford JE, Spliid CB, Golden GJ, Payne NC, Tye MA, Nowell CJ, Griffis ER, Piermatteo A, Grunddal KV, Alle T, Magida JA, Hauser BM, Feldman J, Caradonna TM, Pu Y, Yin X, McVicar RN, Kwong EM, Weiss RJ, Downes M, Tsimikas S, Smidt AG, Ballatore C, Zengler K, Evans RM, Chanda SK, Croker BA, Leibel SL, Jose J, Mazitschek R, Oppermann U, Esko JD, Carlin AF, Gordts PLS (2021). The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection. bioRxiv,

Review

  1. Ramms B, Gordts PLSM (2018). Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. [Review]. Curr Opin Lipidol, 29, (3), 171-179.
  2. Gordts PLSM, Esko JD (2018). The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. [Review]. Matrix Biol, 71-72, 262-282.
  3. Pessentheiner AR, Ducasa GM, Gordts PLSM (2020). Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation. [Review]. Front Immunol, 11, 769.

Book Chapter

  1. Roebroek AJ, Gordts PL, Reekmans (2011). Knock-in approaches. Methods in molecular biology (Clifton, N.J.), 693, 257-75.
  2. Roebroek AJ, Gordts PL, Reekmans (2011). Generation of a series of knock-in alleles using RMCE in ES cells. Methods in molecular biology (Clifton, N.J.), 693, 277-81.

Commentary

  1. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL (2020). Statins and increases in Lp(a): an inconvenient truth that needs attention. Eur Heart J, 41(1), 192-193.
  2. Kawanishi K, Dhar C, Varki A, Gordts PLSM (2020). Reply to Soulillou et al.: Difficulties in extrapolating from animal models exemplify unusual human atherosclerosis susceptibility and mechanisms via CMAH loss. Proc Natl Acad Sci U S A, 117(4), 1847-1848.

Editorial

  1. Yeang C, Gordts PL, Tsimikas S (2017). Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgR(KT) to the List. Circ Res, 120(7), 1050-1052.
  2. Ramms B, Gordts P (2016). Dietary nitrate struggles in atherosclerosis. Atherosclerosis, 245, 71-3.
  3. Pessentheiner AR, Ramms B, Gordts PLS (2018). ANGPTL3 targeting: The power of versatile lipid-lowering. Atherosclerosis, 268, 185-187.
  4. Gordts PLSM, Saltiel A (2019). Hyaluronan as a potential thermogenic rheostat. Nature metabolism, 1(5), 503-504.